- The acquisition will allow
CRED to enter the enterprise spending space. - Professional expense management was a natural proposition for CRED, says CEO
Kunal Shah . Happay manages work-related expenses for over 1 million users globally with approximately $1 billion in annual spends.
The acquisition will allow CRED to enter the enterprise spending space. “While Happay will operate as a separate entity, the team will work closely with CRED leadership to leverage its ecosystem, build distribution, expand the product offering and drive scale,” CRED said in a press note.
Shah, in the media statement, added that CRED has been able to grow rapidly in the last three years by solving the pain of credit card management. He added that now, professional expense management was a natural proposition for the company.
Founded in 2012 by Varun Rathi and Anshul Rai, Happay is a business expense, payments and travel management platform serving over 6,000 businesses. It manages work-related expenses for over 1 million users globally with approximately $1 billion in annual spends.
The company creates 3 million expense reports annually and counts TATA Grow, PwC, Maruti, OYO, Byjus and hundreds of larger enterprises as its customers.
“Happay software stack and in-house payment engine, along with its ease of use, will complement the card management experience that CRED members enjoy for their personal expenses. It is the only unified platform that automates the spend management workflow, a trend that is set to explode in a contactless, paperless world, while ensuring compliance and visibility with an end-to-end audit trail,” the company said.
In October 2021, CRED had acquired alcohol delivery startup
Though the details of the transactions are still unknown, Kunal Shah reportedly joined as the director of Hipbar post this acquisition.
SEE ALSO
Tega Industries’ ₹600 crore IPO opens today; GMP at ₹310
High-speed space junk risk prompts NASA to abruptly delay spacewalk on the International Space Station
Pfizer's top scientist, Mikael Dolsten, tells us the 2 factors that will determine if Omicron is a true threat and shares Pfizer's worst-case-scenario plan